FAKTORI POVEZANI SA SUBJEKTIVNIM OSEĆAJEM UMORA TRI MESECA NAKON PRELEŽANE KOVID-19 INFEKCIJE
Sažetak
Uvod: Subjektivni osećaj umora je jedna od najčešćih post-KOVID-19 manifestacija. Karakteriše ga netolerancija na fizički i kognitivni napor, koji je pojedinac prethodno dobro podnosio, praćena malaksalošću i drugim simptomima.
Cilj: Cilj rada je bio da se ispita učestalost subjektivnog osećaja umora, tri meseca nakon izlečenja, kod pacijenata koji su preležali KOVID-19 infekciju, kao i da se ispitaju povezani faktori.
Metode: Studijom preseka obuhvaćeno je 110 pacijenata koji su preležali KOVID-19 infekciju, a koji su se javili na redovni kontrolni pregled u Zdravstveni centar „Kosovska Mitrovica“, tri meseca nakon izlečenja od akutne infekcije. Korišćen je specijalno konstruisani upitnik, koji se sastojao od dela sa sociodemografskim podacima, dela sa podacima o zdravstvenom stanju i KOVID-19 infekciji kod pacijenta, kao i dela upitnika o samoproceni zdravstvenog stanja nakon KOVID-19 infekcije.
Rezultati: U našem uzorku, od 110 ispitanika, čak 52 su osećala umor. Faktori koji su bili statistički značajno povezani sa subjektivnim osećajem umora, tri meseca nakon izlečenja od KOVID-19 infekcije, su starost ispitanika i hronične bolesti (p < 0,05). Prisustvo povišene telesne temperature i pneumonije tokom bolovanja od KOVID-19 infekcije bili su statistički značajno povezani sa subjektivnim osećajem umora, tri meseca nakon izlečenja (p < 0,05). Hospitalizovani pacijenti i oni koji su bili duže hospitalizovani su takođe češće osećali umor tri meseca nakon izlečenja (p < 0,05).
Zaključak: Subjektivni osećaj umora, tri meseca nakon izlečenja, kao jedna od post-KOVID-19 manifestacija, kao i sledstvena nemogućnost pacijenta da se vrati poslovnim i privatnim obavezama, može predstavljati ozbiljan lični i javnozdravstveni problem, zbog čega je potrebno njegovo adekvatno prepoznavanje i tretiranje.
Reference
- Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324.
- Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, Stepp HE, Clements TP. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 2020 Sep;287(17):3633-3650.
- Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12-16.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Aug 25;324(8):782-793.
- Attaway A H, Scheraga R G, Bhimraj A, Biehl M, HatipoÄŸlu U. Severe covid-19 pneumonia: pathogenesis and clinical management BMJ 2021; 372 :n436
- Lamprecht B. Gibt es ein Post-COVID-Syndrom? [Is there a post-COVID syndrome?]. Pneumologe (Berl). 2020 Oct 8:1-4. German.
- Maltezou HC, Pavli A, Tsakris A. Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines (Basel). 2021 May 12;9(5):497. doi: 10.3390/vaccines9050497. PMID: 34066007; PMCID: PMC8151752.
- Nacul, Luis et al. “European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe.” Medicina (Kaunas, Lithuania) vol. 57,5 510. 19 May. 202
- Roerink ME, van der Schaaf ME, Dinarello CA, Knoop H, van der Meer JW. Interleukin-1 as a mediator of fatigue in disease: a narrative review. J Neuroinflammation. 2017;14(1):16. Published 2017 Jan 21. doi:10.1186/s12974-017-0796-7
- Russell A, Hepgul N, Nikkheslat N, et al. Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. Psychoneuroendocrinology. 2019;100:276-285. doi:10.1016/j.psyneuen.2018.11.032
- "CDC, Chronic Fatigue Syndrome (CFS), Making a Diagnosis" (PDF). Cdc.gov. Archived (PDF) from the original on 2011-10-16.
- Ross SD, Estok RP, Frame D, Stone LR, Ludensky V, Levine CB (May 2004). "Disability and chronic fatigue syndrome: a focus on function". Archives of Internal Medicine. 164 (10): 1098–107.
- Mackay A. A Paradigm for Post-Covid-19 Fatigue Syndrome Analogous to ME/CFS. Front Neurol. 2021 Aug 2;12:701419. doi: 10.3389/fneur.2021.701419. PMID: 34408721;
- Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — united states, march–june 2020) MMWR. (2020) 69:993–8
- Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603–5.
- Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. (2020) 15:e0240784
- Huang C, Huang L, Wang Y, Li X, Ren L et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232.
- Tenforde, Mark W et al. “Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020.” MMWR. Morbidity and mortality weekly report vol. 69,30 993-998. 31 Jul. 2020, doi:10.15585/mmwr.mm6930e1
- Carvalho-Schneider C, Laurent E, Lemaignen A. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2020
- Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: a population-based study. 2021.
- Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. EClinicalMedicine. 2021;36:100899.
